You are here » Home » Companies » Company Overview » Neuland Laboratories Ltd

Neuland Laboratories Ltd.

BSE: 524558 Sector: Health care
NSE: NEULANDLAB ISIN Code: INE794A01010
BSE 00:00 | 20 May 1026.75 2.80
(0.27%)
OPEN

1030.15

HIGH

1040.35

LOW

1020.55

NSE 00:00 | 20 May 1024.80 3.25
(0.32%)
OPEN

1026.70

HIGH

1039.55

LOW

1019.95

OPEN 1030.15
PREVIOUS CLOSE 1023.95
VOLUME 3283
52-Week high 2309.65
52-Week low 1000.00
P/E 20.73
Mkt Cap.(Rs cr) 1,317
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1030.15
CLOSE 1023.95
VOLUME 3283
52-Week high 2309.65
52-Week low 1000.00
P/E 20.73
Mkt Cap.(Rs cr) 1,317
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Neuland Laboratories Ltd. (NEULANDLAB) - Chairman Speech

Company chairman speech

Dem/Readeu

The COVID-19 pandemic has had the most significant economic and socialimpact on the world in recent memory. At Neuland the strength and agility we have builtinto our business enabled us to deliver a steady performance despite the externalchallenges. I am incredibly proud of our people for their commitment and contribution inthese difficult times. Our priorities remain the safety of our people maintainingbusiness continuity to ensure timely delivery of our products to support customers andthrough excellent people and processes meet the high standards they have come to expectfrom Neuland.

Our performance was driven by growth in both the business verticals ofGeneric Drug Substances (GDS) and Custom Manufacturing Services (CMS). While the uptick inGDS business was led by customer acquisition and our continued efforts in productlifecycle management the CMS business is seeing the fruition of our sustained focus onbuilding strong customer relationships and the right pipeline of projects. Much of thecredit for our success also goes to our strong well- balanced teams across functions whoworked closely to serve customer needs in an extraordinary year. As we look to the futurewe believe that the continued emphasis on growing our capability fosteringcross-functional collaboration and driving continuous improvement makes us well-positionedto scale business growth.

Across both verticals meeting customer needs and exceeding theirexpectations is a fundamental part of our operating model and our values.

Our uncompromising commitment to quality compliance and safetyunderpins this customer focus. In this regard the deep understanding of regulatoryrequirements that we have amassed by serving highly regulated markets for over 25 yearstogether with our intense focus on upholding the highest quality and safety standards inour operations continues to be a key business differentiator.

We continue to build on our R&D capabilities aligned with our goalto be a preferred partner to innovator companies for contract research and manufacturing.

The knowledge and skills of our R&D team also play a critical rolein sustaining our market position in the GDS business. I am pleased to share that duringthe year we have further enhanced our R&D ; expertise and infrastructure to enable us; to better serve our customers and deepen ; our engagement with them.

Guided by the foresight of our ; management team we have been ;proactively pursuing supply chain ; diversification over the past few years to reduce ourdependence on any single geography. The business strategy has; worked to our advantage asreflected in our almost interruption-free operations and timely deliveries in a year whenglobal supply chains were disrupted due to the pandemic breakout. We have beenaccelerating the integration of technology in our operations to leverage greaterefficiencies. Our strong focus on operational excellence is also evidenced in our team'sefforts to optimise processes improve yields and lower costs. This relentless drive forefficient execution enhances our reputation as a leading API manufacturer and anend-to-end solution ; provider for the pharmaceutical industry's ; complex chemistryneeds.

As we look to take our business to the ; next level we recognise thatstrong ; leadership and future talent pipeline is ; a strategic imperative. We areactively ; looking at bringing the best global talent ; for strategic roles and providingthem ; with the right kind of environment so that they can perform. We also continue toemphasise building an organisation where people are constantly learning especiallyessential in our kind of business and for driving professional satisfaction.

Entering FY 2022 the world continues to fight the global healthcrisis. At Neuland we are implementing strict health and safety measures across all oursites to ensure that we can operate at or close to normal operating levels through thisperiod of uncertainty. While fiscal prudence remains the order of the day we are makinginvestments in critical areas such as quality systems infrastructure and R&D tomaximise opportunities for future growth.

Looking forward we are well-positioned to benefit from our excellentproduct portfolio strong CMS project pipeline and growing capabilities. We are workingtowards enhancing our customer base in our key markets of the US Japan and Europeespecially in the context of our CMS business. Finally we will use the momentum that wehave generated over the years along with the learnings of the past to generate bettervalue.

On behalf of the Board I would like to thank our customers andshareholders for their continued support and our employees for their exceptional work andcommitment. I look forward to our continued success in achieving our goals and deliveringstrong performance.

Warm Regards

Dr. Davuluri Rama Mohan Rao

.